Conferences
    October 26, 2022

    ESMO’22 Recommended Abstracts in RENAL CANCERS

    Robert A. Figlin, MD,  Editor-in- Chief of the Kidney Cancer Journal. These recommended abstracts from ESMO…
    Cancer
    October 26, 2022

    Gene activity Can Provide Clues for Risk of Kidney Cancer Spreading

    OCTOBER 17, 2022 – 4 MINUTES READ     The activity of four specific genes in…
    Cancer
    October 26, 2022

    A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies

    Robert A Figlin, MD, FACP1 , Senthil Pazhanisamy, PhD2 1. Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute,…
    Conferences
    October 26, 2022

    2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy

    ESMO’22 Special Robert A. Figlin, MD, FACS Cedars Cinai Cancer Center, Los Angeles, CA Correspondence:…
    Kidney Cancer
    October 26, 2022

    Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors

    Grayce N. Selig, MD1 Christopher J. Hoimes, DO,2 Joe Bible, PhD,3 Daniel J. George, MD,2 Michael R. Harrison, MD2…
    ASCO
    July 28, 2022

    Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting

    . Updated Yasser Ged,1 and Nirmish Singla2,* 1) Department of Oncology, The Johns Hopkins University School…
    Cancer
    July 28, 2022

    Engineered T-Cell Therapy: The Next Direction for RCC Immuno-oncology?

    JJ H. Zhang, MD,1 Neal A. Patel, MD,1 Alexandra Drakaki, MD, PhD,1,2 Allan J. Pantuck, MD1,* 1) Institute…
    Kidney Cancer
    July 28, 2022

    Comparison of Papillary Renal Cell Carcinoma Type 1 and Type 2: A Secondary Data Analysis

    Melissa Paquin, PhD,1 Tracy Fasolino, PhD, FNP,2 Joe Bible, PhD,3 Mary Beth Steck, PhD,2 Joel Williams, PhD.4 1. Clemson…
    GU CANCERS
    July 28, 2022

    Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma

    Robert J Motzer, MD 1, Toni K Choueiri, MD 2, Laurence Albiges, MD, PhD 3,Robert…
    Kidney Cancer
    September 15, 2021

    From Gene Discovery to a FDA approval; Belzutifan’s Fascinating Journey at UTSW

    Published on: August 21, 2021    A novel kidney cancer drug developed from UT Southwestern Medical…
      Conferences
      October 26, 2022

      ESMO’22 Recommended Abstracts in RENAL CANCERS

      Robert A. Figlin, MD,  Editor-in- Chief of the Kidney Cancer Journal. These recommended abstracts from ESMO 2022 Annual meeting have been…
      Cancer
      October 26, 2022

      Gene activity Can Provide Clues for Risk of Kidney Cancer Spreading

      OCTOBER 17, 2022 – 4 MINUTES READ     The activity of four specific genes in the cancer cells seems to…
      Cancer
      October 26, 2022

      A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies

      Robert A Figlin, MD, FACP1 , Senthil Pazhanisamy, PhD2 1. Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Health System, Los Angeles…
      Conferences
      October 26, 2022

      2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy

      ESMO’22 Special Robert A. Figlin, MD, FACS Cedars Cinai Cancer Center, Los Angeles, CA Correspondence: RAF There was never a…
      Back to top button